GSK targets Syndivia’s prostate cancer ADC in £268m buy - Pharmaceutical Technology
GSK Acquires Syndivia's Prostate Cancer ADC GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment. Despite having its own…